Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
68 hedge funds and large institutions have $158M invested in Eiger BioPharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 24 increasing their positions, 10 reducing their positions, and 10 closing their positions.
150% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 10
140% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 10
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
34% more capital invested
Capital invested by funds: $118M → $158M (+$40.2M)
28% more funds holding
Funds holding: 53 → 68 (+15)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$26M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$11.8M |
| 3 |
6CM
683 Capital Management
New York
|
+$10.5M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$7.27M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$5.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$15.2M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$4.1M |
| 3 |
IVM
InterWest Venture Management
San Francisco,
California
|
-$3.85M |
| 4 |
JP Morgan Chase
New York
|
-$927K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$600K |
EIGR Hedge Fund Activity: Q4 2018 in Review
68 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q4 2018, worth a combined $158M — up 34% from $118M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new EIGR positions and 10 closed out — a net gain of 15 holders — while 24 added to existing stakes and 10 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $26M. The largest seller was Jennison Associates, exiting entirely with an estimated $15.2M sold.
- 68 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q4 2018, up from 53 in Q3 2018.
- Funds reported $158M of Eiger BioPharmaceuticals, Inc. stock for Q4 2018, up 34% quarter-over-quarter.
- 25 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q4 2018 and 10 closed out, a net change of +15 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q4 2018 was RA Capital Management, an estimated $26M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q4 2018 was Jennison Associates, an estimated $15.2M sold.
Based on aggregated 13F filings for Q4 2018.